RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop cancer cells from growing. Giving vaccine therapy together with GM-CSF may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects of vaccine therapy and GM-CSF in treating patients with acute myeloid leukemia, myelodysplastic syndromes, non-small cell lung cancer, or mesothelioma.

Start Date01 Oct 2006

Sponsor / Collaborator

Memorial Sloan Kettering Cancer Center

[+2]

100 Clinical Results associated with WT-1 analog peptide vaccine(NCI)

100 Translational Medicine associated with WT-1 analog peptide vaccine(NCI)

100 Patents (Medical) associated with WT-1 analog peptide vaccine(NCI)

Literatures (Medical) associated with WT-1 analog peptide vaccine(NCI)

01 Jun 2020·Pediatrics International

¹³¹I‐MIBG therapy with WT‐1 peptide for refractory neuroblastoma

Article

Author: Hosoya, Yosuke ; Manabe, Atsushi ; Sugiyama, Minako ; Seigo, Kinuya ; Iguchi, Akihiro

This article describes about the ¹³¹I-MIBG therapy with WT-1 peptide for refractory neuroblastoma.After a chemotherapy course of vincristine, irinotecan, and cyclophosphamide and two chemotherapy courses of etoposide, cyclophosphamide, and topotecan, peripheral blood stem cell harvest (PBSCH) was performed.Subsequently, chemotherapy courses were administered after resecting the right adrenal tumor.

01 Oct 2010·Cancer Immunology, ImmunotherapyQ2 · MEDICINE

WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer

Q2 · MEDICINE

Article

Author: Sara Bekele ; Jedd Wolchok ; Tatyana Korontsvit ; Tao Dao ; Peter Maslak ; Jianda Yuan ; Hao Li ; Lee M. Krug ; Victoria Zakhaleva ; David A. Scheinberg ; William Travis ; Andrew B. Brown ; Leslie Tyson

BACKGROUNDThe transcription factor, WT1, is highly overexpressed in malignant pleural mesothelioma (MPM) and immunohistochemical stains for WT1 are used routinely to aid in its diagnosis. Using computer prediction analysis we designed analog peptides derived from WT1 sequences by substituting amino acids at key HLA-A0201 binding positions. We tested the safety and immunogenicity of a WT1 vaccine comprised of four class I and class II peptides in patients with thoracic neoplasms expressing WT1.METHODSTherapy consisted of six subcutaneous vaccinations administered with Montanide adjuvant on weeks 0, 4, 6, 8, 10, and 12, with 6 additional monthly injections for responding patients. Injection sites were pre-stimulated with GM-CSF (70 mcg). Immune responses were evaluated by DTH, CD4 T-cell proliferation, CD8 T-cell interferon gamma release, intracellular cytokine staining, WT1 peptide MHC-tetramer staining, and cytotoxicity against WT1 positive tumor cells.RESULTSNine patients with MPM and 3 with NSCLC were vaccinated, with 8 patients receiving at least 6 vaccinations; in total, 10 patients were evaluable for immune response. Six out of nine patients tested demonstrated CD4 T-cell proliferation to WT1 specific peptides, and five of the six HLA-A0201 patients tested mounted a CD8 T-cell response. Stimulated T cells were capable of cytotoxicity against WT-1 positive cells. Vaccination also induced polyfunctional CD8 T cell responses.CONCLUSIONSThis multivalent WT1 peptide analog vaccine induces immune responses in a high proportion of patients with thoracic malignancies with minimal toxicity. A randomized trial testing this vaccine as adjuvant therapy in MPM is planned.

100 Deals associated with WT-1 analog peptide vaccine(NCI)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Myeloid Leukemia	Phase 1	US	National Cancer Institute	01 Oct 2006
Acute Myeloid Leukemia	Phase 1	US	Innovive Pharmaceuticals, Inc.	01 Oct 2006
Mesothelioma, Malignant	Phase 1	US	Innovive Pharmaceuticals, Inc.	01 Oct 2006
Mesothelioma, Malignant	Phase 1	US	National Cancer Institute	01 Oct 2006
Myelodysplastic Syndromes	Phase 1	US	National Cancer Institute	01 Oct 2006
Myelodysplastic Syndromes	Phase 1	US	Innovive Pharmaceuticals, Inc.	01 Oct 2006
Non-Small Cell Lung Cancer	Phase 1	US	National Cancer Institute	01 Oct 2006
Non-Small Cell Lung Cancer	Phase 1	US	Innovive Pharmaceuticals, Inc.	01 Oct 2006
Peritoneal Neoplasms	Phase 1	US	National Cancer Institute	01 Oct 2006
Peritoneal Neoplasms	Phase 1	US	Innovive Pharmaceuticals, Inc.	01 Oct 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00398138 (CTgov)	Phase 1	Acute Myeloid Leukemia \| Mesothelioma, Malignant \| Non-Small Cell Lung Cancer \| Myelodysplastic Syndromes \| Peritoneal Neoplasms	22	immunoenzyme technique+WT-1 analog peptide vaccine+sargramostim	tepxrypzus(znisvhnrpj) = shuemwlwff ulxuylglwi (dlxywfzhcj, gyxakcovqd - jmdifnzhgd) View more	-	02 Mar 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

WT-1 analog peptide vaccine(NCI)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation